



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease / Macchiagodena, Marina; Pagliai, Marco; Procacci, Piero. - In: JOURNAL OF MOLECULAR GRAPHICS & MODELLING. - ISSN 1093-3263. - STAMPA. - 110:(2022), pp. 108042-108050. [10.1016/j.jmgm.2021.108042]

Availability:

The webpage <https://hdl.handle.net/2158/1245574> of the repository was last updated on 2021-10-17T12:59:47Z

Published version:

DOI: 10.1016/j.jmgm.2021.108042

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease

Marina Macchiagodena, Marco Pagliai, and Piero Procacci*

*Dipartimento di Chimica "Ugo Schiff", Università degli Studi di Firenze, Via della
Lastruccia 3, Sesto Fiorentino, I-50019 Italy*

E-mail: procacci@unifi.it

Abstract

We have studied the non-covalent interaction between PF-07321332 and SARS-CoV-2 main protease at the atomic level using a computational approach based on extensive molecular dynamics simulations with explicit solvent. PF-07321332, whose chemical structure has been recently disclosed, is a promising oral antiviral clinical candidate with well-established anti-SARS-CoV-2 activity *in vitro*. The drug, currently in phase III clinical trials in combination with ritonavir, relies on the electrophilic attack of a nitrile warhead to the catalytic cysteine of the protease. Nonbonded interaction between the inhibitor and the residues of the binding pocket, as well as with water molecules on the protein surface, have been characterized using two different force fields and the two possible protonation states of the main protease catalytic dyad HIS41-CYS145. When the catalytic dyad is in the neutral state, the non-covalent binding is likely to be stronger. Molecular dynamics simulations seems to lend support for an inhibitory mechanism in two steps: a first non-covalent addition with the dyad in neutral form and then the formation of the thiolate-imidazolium ion pair and the ligand relocation

for finalising the electrophilic attack.

Introduction

In the ongoing COVID-19 pandemic, viral infectivity is known to have been recently boosted by at least four different variants in England, Brazil, South Africa and India,¹ all involving mutations on the Spike (S) structural protein. It seems reasonable to expect that SARS-CoV-2 mutational activity on S will wane to some extent vaccine efficacy as the pandemics evolve. The need for an effective antiviral drug against COVID-19 is hence more urgent than ever. In this respect, the SARS-CoV-2 main protease (3CL^{pro}) is probably one of the most promising biological targets.² While the mutation rate is high on S, the non structural 3CL^{pro} is highly conserved in the coronaviridae family,³ and is responsible for the generation of the entire virus replication machinery, by cleaving the long polyproteins expressed by the virus RNA upon cell entry.

Considerable efforts have been devoted to the identification an effective antiviral agent for SARS-CoV-2 via computational approaches,⁴⁻¹³ combing different methodologies and analyzing also well-known chemical compounds. On the 6th of April 2021, Pfizer disclosed the structure of a 3CL^{pro} inhibitor (Figure 1), named PF-07321332, exhibiting nanomolar affinity and capable of suppressing virus replication in human cells at sub-micromolar concentrations.¹⁴ The design of PF-07321332 is similar to that of the ML1000 peptidomimetic molecule,¹⁵ a covalent reversible Michael 3CL^{pro} inhibitor with submicromolar activity bearing an alpha-keto-amide moiety flanked by two proline-mimetic groups. In PF-07321332, the alpha-keto-amide has been replaced by a nitrile group, acting as a Michael acceptor.¹⁶

The catalytic mechanism of the cysteine proteases depends on a HIS/CYS catalytic




Figure 1: Structure of PF-07321332 and labelling of groups used for the analysis.

dyad (HIS41-CYS145 in SARS-CoV-2 3CL^{pro}). In Chymotrypsin-like proteases, such as 3CL^{pro}, the nucleophilic attack of the cysteine thiolate is believed to be a concerted process whereby the covalent binding of the substrate is assisted by the histidine, functioning as a proton acceptor from the SH group. In the serine Chymotrypsin protease, the N ϵ deprotonated catalytic HIS57 is an H-bond donor on the N δ 1 protonated site for a vicinal ASP102 residue, making HIS57 more basic, hence favouring the proton transfer (PT) from SER195 upon ligand docking.¹⁷ In SARS-CoV-2 3CL^{pro}, such role is apparently played by a water molecule, tightly H-bonded to N δ 1 of HIS41, and revealed in X-ray^{18,19} and neutron scattering experiments at room temperature.²⁰ Papain-like proteases, on the other hand, are believed to act by a thiolate-imidazolium ion pair mechanism, with the dyad already in the zwitterionic form in the native unligated state.^{16,21} In this regard, neutron scattering experiments²⁰ conducted at pH 6.6 and room temperature have shown that HIS41 is protonated and CYS145 is deprotonated on the SARS-CoV-2 3CL^{pro} protein also. This is at variance with the results presented on a previous study by the same authors,¹⁸ in agreement with the consensus base catalysis mechanism²² and with the results obtained in Ref.²³ on the homologous SARS-CoV-1 3CL^{pro}, where the measured pKa of CYS (8.3) and HIS (6.4) are consistent with a general base catalysis Chymotrypsin mechanism and cannot be explained by a thiolate-imidazolium ion pair model. Most recently, a thorough MD study on the dimer²⁴ showed that the ion-pair configuration of the dyad is not compat-

ible with a catalytically competent binding mode for peptide substrates. Substrate docking on the 3CL^{pro} with the dyad in *neutral form* is hence supposed to favor the CYS to HIS PT²⁵ preceding the acylation step in the catalysis.

Recently, the catalytic mechanism in 3CL^{pro} was investigated using hybrid QM/MM multi-scale hybrid methods.^{25,26} Both these studies agree on the fact that in the apo (unligated) form, the neutral state for the dyad is significantly more stable than the zwitterionic state. Regarding the role of the ligand in the holo form, however, these studies strikingly predict an *opposite* effect on the ion-pair state, stabilising in Ref.²⁵ and destabilising in Ref.²⁶ One weak point of these QM/MM approaches for the holo forms is that the latter are prepared²⁵⁻²⁷ starting from the X-ray structures *where the ligand is already covalently bound* to CYS and that were presumably obtained from protein stock pre-incubated with the ligand. The X-ray structure, on the other hand, is not necessarily similar to the actual initial non covalent bonding pose as the transition state involving the substrate and the binding site must be the result of a concerted process with a C145 to H41 PT transfer induced by the ligand *non covalent* docking, followed by a structural modification involving both the ligand and the nearby residues (including the oxyanion hole²⁸) to arrive at the covalently bonded form seen in the ligand incubated samples. In other words, what is important for 3CL^{pro} inhibition is the strength of such *unknown* non-covalent association. This non-covalent affinity, $1/K_m$, of the initial Michaelis-Menten complex involving the inhibitor must be stronger than that of a typical 3CL^{pro} substrate corresponding to a substrate-enzyme dissociation constant of the order of -4:-5 kcal/mol.²³

Covalent inhibitors such as PF-07321332 are hence generally designed incorporating the electrophilic group into peptidomimetic substrates that are already known to bind non covalently with micromolar affinity.²⁹ The structural stability of the binding site as well as the modulation of the affinity for Michael inhibitors in 3CL^{pro} with different protonation states of the dyad residues was recently assessed by molecular dynamics (MD) simulations.³⁰ It is hence of interest to study the effect of the protonation states of the

dyad in the conformational states of the PF-07321332 compound and to characterise its modality of binding *preceding* to the nucleophilic attack. To this end we have performed docking calculations and extensive MD simulations with 3CL^{pro} with the dyad in neutral and zwitterionic form. MD calculations were done using two popular force fields (FFs) for protein simulation, namely AMBER³¹ and OPLS-AA.³² We have found that both FFs predict a higher conformational activity of the binding site when the dyad is in the neutral form. Non-covalent binding, as inferred from the ligand-receptor distance distributions, seems to be stronger when 3CL^{pro} catalytic dyad is the neutral form. Water penetration in the catalytic pocket is found to be highly enhanced when HIS41 and CYS145 are in their charged states, irrespective of the FF used. Although the binding modality have some significant differences when using AMBER or OPLS-AA, both FFs agree on the fact that the binding pattern of PF-07321332 is dependent of the protonation state of the dyad, with the nitrile group (Michael acceptor) closer to the dyad when the latter is in the zwitterionic state.

Methods

3CL^{pro} is composed of two loosely coupled units that fold independently,³³ namely the Chymotrypsin-like domains I+II (residues 1-197), hosting the catalytic site, and the cluster of helices domain III (residues 198-304). It is well known that efficient viral polyproteins cleavage occurs when 3CL^{pro} is in the dimeric form.³⁴ The 3CL^{pro} dimer has two symmetric extended clefts for optimal (linear) peptide chain adhesion.³⁵ The dimer interface involves the N-terminus of domain I+II and the C-terminus of domain III with no participation of the distal and solvent exposed catalytic site.^{22,35} When expressed independently, while domain III has no role in the catalysis,³³ the isolated domain I+II is still capable of cleaving a 14-mer peptidic substrate mimicking the N-terminal autocleavage sites of the SARS 3CL^{pro}, although with a much smaller turnover number with respect to the 3CL^{pro} dimer.³³ The inhibition power of small (4-mer) peptidomimetic compounds such as PF-07321332, fitting

comfortably in the binding pocket, can hence be reasonably assessed using domain I+II only.³⁵

Docking calculation were performed using AutoDock Vina.³⁶ Vina is known to improve the average accuracy of the (non covalent) binding mode predictions on the well established DUD-E benchmark set³⁷ of more than 50% compared to AutoDock4, and it was found to be a strong competitor against popular commercial programs, resulting at the top of the pack in many cases. In a recent paper,³⁸ the ability to correctly reproduce the binding modes in SARS-CoV-2 3CL^{pro} of popular docking programs, including Vina, was questioned. In this study,³⁸ 85 co-crystal 3CL^{pro} structures with noncovalently bound ligands were examined. The authors found that in only 15% of these structures, Vina was able to identify the correct crystallographic pose (within a rather conservative 2 Å RMSD tolerance) with the lowest scoring function. Examining their data, we found that in about 60% of the 85 co-crystal structures, the ligand was outside the binding sub-sites S1 and S1' of the catalytic pocket of the peptidase, either bound in the S2-S4 sub-sites or at the distal dimer interface or on the surface of domain I+II and III. Most ligands were small and weakly active (especially when far from catalytic site). As all heteroatoms except the ligand were removed prior to docking, the binding modality of small ligands, possibly cohabiting with cavity water molecules in the binding pocket, might can be harder to predict when the latter are not accounted. We hence decided to repeat their analysis using Vina on the 28 3CL^{pro} co-crystal structures where the ligand had at least one moiety in the S1 sub-site, where the 3CL^{pro} substrate P1(GLN) specifically binds. We have found that in about \simeq 35% of these 28 structures Vina is able to identify the correct (crystallographic) binding pose with a tolerance of less than 3 Å RMSD, and in \simeq 70% of the cases the crystallographic binding mode was found among the poses within 0.3 kcal/mol of the best scoring pose. As observed in Ref.,³⁸ Vina performances tend to improve for bulky ligands such as PF-07321332. Full results of this analysis can be found in the ESI.

PF-07321332 was docked to the 3CL^{pro} binding site (6LU7³⁹) of domain I+II, con-

sidering both states (neutral and zwitterionic) of the catalytic dyad. **The calculation runs docking experiments using a so-called gradient optimization algorithm** with the box center placed at the midpoint of the vector connecting S_γ of C145 to N_ϵ of H41 with a cubic box size of 1.8 nm side length. The protonation state of all residues except H41 and C145 was assigned using the PropKa program.⁴⁰ Using a set of 28 co-crystal structures, we checked that predicted Vina binding poses are essentially unchanged when docking the catalytic site on the single domain I+II and on the full protomer (see Figure S1 in ESI).

MD simulations were carried out for the Chymotrypsin-like catalytic domain I+II^{22,41} of the two isoforms using, in turn, the Amber99sb-ildn⁴² and the OPLS-AA/M FFs³² with the GROMACS code⁴³ (version 2018.8). In the H-C isoform, H41 was assigned to the tau-tomer with the protonated N_δ .²⁵ The potential parametrization for the PF-07321332 ligand was generated using two web interfaces: PrimadORAC⁴⁴ for AMBER FF and LigParGen⁴⁵ for OPLS-AA FF. Starting from the best scoring ligand pose, we have performed extensive molecular dynamics simulations^{43,46} with explicit solvent.^{47,48} Further methodological aspects are provided in ESI.

Results

Docking calculations

In Figure 2 we show the best score poses of the ligand obtained in the two protein isoforms. The binding pattern appears to be strongly affected by the protonation state. For the neutral dyad (Figure 2a), CYS145 (not included in the LigPlot diagram) and HIS41 are approached by the hydrophobic ligand group (4)-(5), and (7), respectively (for groups numbering see Figure 1). In the zwitterionic state, the dyad (HIS41 not included in LigPlot diagram) is again approached by a weakly hydrophobic moiety (trifluoro group (9)).

In the best Vina pose, the nitrile warhead is far from the dyad in both forms: -CN points to GLY143 with the oxo-pyrrolidine group being close to the neutral dyad H41-C145; when




Figure 2: 2D representation of the best docking poses in the binding site obtained with LigPlot.⁴⁹ The nitrile group is circled in magenta. The dyad residues are indicated with black dashed squares and the hydrogen bonds with dashed green lines. a) Dyad in neutral state. b) Dyad in zwitterionic state.

H41-C145 is in the zwitterionic state, $-CN$ is pointing to GLN189 and two hydrogen bonds (involving GLU166 and GLY143) are present. Strikingly, Vina yields for the two isoforms nine poses within 1:1.5 kcal/mol score only, with root mean square deviations (RMSDs) from the best mode ranging from 2 to 5 Å, indicating that binding can occur in quite

disparate modalities in both isoforms and/or that the ligand might experience significant conformational activity in the binding site. As shown in the Table S4 of the ESI, the minimum distance between the nitrile carbon of PF-07321332 and the S_γ of CYS145 is found in the neutral isoform at 4.3 Å for pose number 7 with a binding free energy 1.3 kcal/mol higher than that of the best Vina pose.

MD simulations

Protein motions

In Figure 3, we report the time record of the heat-maps of the RMSD of the protein backbone atoms along the primary sequence of domain I+II. The reference structure is the starting docking structure. The corresponding time records of the overall backbone RMSD are reported in ESI (Figure S2). The protein fold, after an initial assessment, appears to be stable in all four simulations. In going from the neutral to the zwitterionic form, a remarkable RMSD increase around the catalytic histidine is observed with AMBER, possibly induced by rapid rearrangement of the ligand. At the same time the alpha-helical region 50-70 seems to decrease its mobility in the charged form. The same features, albeit somewhat attenuated, can be observed using OPLS-AA.

A heat-map based on about 100 PDB crystal structures of 3CL^{pro} (free and inhibited with covalent and non covalent ligands) was reported in Figure 8 of Ref.²² The structural differences in the map were assumed to depend more on crystal packing than on the presence or absence of ligands or the temperature of the diffraction experiment. Strikingly, the region of maximum experimental variability of the I+II domain is comprised precisely in the 40-70 residue range including the residues H41, M49, Y45 of the S2 region, as observed in our AMBER simulation in the neutral isoform (Figure 3). Given that more than 50% of the X-ray structures examined in Ref.²² refer to ligand-free (apo) proteins or proteins with a *non-covalent* ligand, it is tempting to infer that the neutral isoform is the




Figure 3: Heat-maps of RMSD of the protein backbone (domain I+II) for the MD simulations using the two FFs and the two states of the catalytic dyad (H41-C145). The position of the catalytic dyad in the primary sequence is highlighted in yellow.

most likely dyadic state in physiological conditions as resulted with the amber99sb-ildn FF. The latter FF was found to be more reliable than OPLS-AA on the long time-scale in a recent comparative MD study on ubiquitin and G3 proteins.⁵⁰

Ligand motions

In Figure 4 we show the distribution of the distances between the centers of mass (COM) of the ligand and the protein. With the AMBER FF, we observe a marked increase of the average COM-COM distance with a significant widening of the distribution in going from the neutral to the zwitterionic isoform. With OPLS-AA, again we observe a widening of the

distribution in the zwitterionic isoform with the average COM-COM distance exhibiting a minor shift of about 1 Å in the opposite direction. As ligand-protein COM-COM distribution is strictly related to the equilibrium constant via the associated potential of mean force,^{51,52} the sharp and narrow distribution observed in the H-C state seems to indicate that PF-07321332 has a higher *non-covalent* affinity for this form rather than for the H⁺-C⁻ isoform where the ligand COM-COM distribution is wider. The increased spread of the




Figure 4: COM-COM distribution calculated from MD simulations. In blue AMBER FF and neutral dyad, in red AMBER FF and zwitterionic dyad, in cyan OPLS-AA FF and neutral dyad and in magenta OPLS-AA FF and zwitterionic dyad.

distributions seen with both AMBER and OPLS-AA indicates that PF-07321332 is more conformationally active when the catalytic dyad is in the charged state. This fact is further confirmed by the time record of the RMSD of the ligand heavy atoms (Figure S3 of ESI) and by the histogram of the dihedral angle connecting groups (2) and (3) (Figure S4 of ESI).

Solvent behaviour

A water molecule (detected in most of the recent crystal structures of free and inhibited 3CL^{pro}²²) has been suggested to surrogate the role of ASP102 in the canonical Chymotrypsin catalytic reaction by assisting in PT from CYS145 to HIS41 and by stabilizing the positive charge accumulated on HIS41 in the Chymotrypsin acid-base mechanism. In

3CL^{pro}, this water is believed to function as an H-bond acceptor from the protonated N δ 1 of HIS41.²⁵ In Figure 5, we report the integrated radial distribution function, $g_{H\delta 1-OW}(r)$, for the contact H δ 1(H41)-O(H₂O) (with OW labelling the oxygen in water molecules) obtained in the simulations. According to both AMBER and OPLS-AA, water molecules




Figure 5: Integral of the radial distribution function for the H δ 1(H41)-O(H₂O) contact in the four simulations. In the inset, the integral of the N ϵ 2(H41)-H(H₂O) contact.

appear to penetrate the PF-07321332 engaged binding site region much more effectively when the dyad is in the zwitterionic state. Within a distance of 10 Å from H δ 1(H41), about 30 and 25 solvent molecules are found with OPLS-AA and AMBER, respectively. The $g_{H\delta 1-OW}(r)$ function integrates at the same distance of 10 Å to about 1/3 of the molecules when the dyad is in the neutral state. This fact appears to be consistent with a weaker binding in the H⁺-C⁻ isoform as inferred by the COM-COM distance distributions (see Figure 4): water tends to occupy more the cavity when the dyad is the zwitterionic state, competing with the ligand. In the OPLS-AA simulations, a water molecule acts as an H-bond acceptor to N δ 1-H δ 1 of H41 for the entire 100 ns in both isoforms. In AMBER, while in H⁺-C⁻ such H-bonded water is always present, in the H-C state, a water molecule acts as an H-bond donor to the N ϵ 2 of H41, while the H δ 1(H41) hydrogen is shared by a water oxygen and a carbonyl oxygen of H163. The higher occupancy of solvent molecules in the zwitterionic form has an impact on the solvent exposure of the bound ligand, which, according to both FFs, has an average number of surrounding water molecules N_w within

a distance of 6 Å of $N_w \simeq 30$ and $N_w \simeq 25$ using the OPLS and AMBER FF, respectively.

Ligand-protein interactions

From the RMSD time record of the ligand heavy atoms (Figure S3 of ESI), we can see that PF-07321332 evolves rapidly to a stable pose about 2.5 Å away from the initial docking pose in the protein with the neutral dyad. This behaviour is similar when using OPLS-AA or AMBER and is reflected in the narrow ligand-protein COM-COM distance distribution observed for the neutral dyad state in both FFs (Figure 4). For the isoform with $H^+ - C^-$, both FFs predict an enhanced mobility of the ligand in the binding site. With OPLS-AA, we observe an abrupt rearrangement of the ligand pose during the 100 ns simulation with the RMSD raising to 3.5 Å and back to 2.5 Å (magenta curve of Figure S3 in ESI), rather than the frequent conformational transitions in the subnanosecond time-scale observed when using the AMBER FF (red curve of Figure S3 in ESI).

Concerning the detailed ligand-protein interaction, again OPLS-AA and AMBER yield similarities as well as important differences. In Figure 6 we show the ligand-residue contact map computed in the four simulations. The ligand has been sectioned into 9 groups (Figure 1 for groups labels) with the index (2) referring to the nitrile moiety. A ligand group is assumed to be in contact with a given protein residue if any group-residue atom-atom distance is found below 4.5 Å threshold. The heat-bar on the right of the maps refers to the contact probability.

The contact maps of Figure 6 inherit some features from Vina-generated corresponding starting structures. Concerning the H-C isoform, the oxo-pyrrolidine group (1), mimicking the glutamine P1 residue of the 3CL^{PRO} substrate, is found mostly near the triad THR25, THR26, LEU27 according to both FFs, as in the docked LigPlot structure reported in Figure 2. The same applies to the terminal trifluoro group (9) found to insist in the region R188, Q189, T190 in the H-C form using both FFs, as in the docked structure of Figure 2a. For the $H^+ - C^-$ protein, the oxo-pyrrolidine group (1) of the ligand is this time in contact with

the terminal end of the domain I+II (187-194) according to both AMBER and OPLS-AA, a feature that is also observed in the starting Vina structure (Figure 2), while the trifluoro group (9) remains mostly solvent-exposed in AMBER and, to a less extent, in OPLS-AA, drifting away from the Vina position where $-\text{CF}_3$ is found near the catalytic negatively charged C145. In the MD simulations of the $\text{H}^+ - \text{C}^-$ isoform, the nitrile group relocates significantly with respect to the starting Vina pose, approaching, especially for the AMBER case, to the catalytic C145.

As a general trend, the PF-07321332 contact matrix obtained in the simulations appears to be roughly diagonal and anti-diagonal when the dyad is in the zwitterionic and neutral state, respectively. In the anti-diagonal form (blue maps, neutral dyad), groups (7) to (9) of the ligand tend to move in the proximity of the region 163-194 of domain II, while group (1) moves towards the terminal region of the domain I (region 20-50). The ligand orientation in the $\text{H}^+ - \text{C}^-$ form generates an approximately diagonal pattern with the ligand terminal groups (1) and (7)-(9) on domain II and I, respectively. These non bonded conformations are at variance with the available X-ray structures of similar *covalently bound* peptidomimetic compounds with the oxo-pyrrolidine moiety (surrogating a GLN) near S1 protein sub-site (defined by the [residues⁵³ S144, H163, E166 and H172](#)).

Neutral dyad (H-C) isoform: According to AMBER (top left panel in Figure 6), the oxo-pyrrolidine group (1) insists in the region 22-49 including the catalytic H41, but apparently not in strict contact with C145. The neighboring nitrile group (2) remains mostly solvent-exposed with loose contacts with GLY143.

Tighter contacts in the protein region 142-145 (hence including C145) are seen with the central amide group (3). The trifluoro group (9) lies mostly near the polar residues Q189, R188 and D187 while the trimethyl hydrophobic moiety (7) is engaging in stable contacts with H163 and H164. When using OPLS-AA, the contact map shows similarities as well as important differences. For example, the nitrile group is rather far from the neutral dyad according to both FF. However, when using OPLS-AA, this group is stably in




Figure 6: Contact maps between ligand groups (labeling in Figure 1) and protein residues obtained from MD simulations with AMBER and OPLS-AA FFs and neutral dyad (H–C), AMBER and OPLS-AA FFs and zwitterionic dyad (H⁺–C⁻). The heat-bar on the right of the plot represents a contact probability. Values of 1 for the contact probability imply that the ligand group has been found in contact with the given residue in all configurations during the 100 ns simulation.

contact with T45 and C44 rather than mostly solvent-exposed as with AMBER. OPLS-AA predicts a very tight contact between the trifluoro terminal group and the hydrophobic residues P168 L167, an interaction that is not present when using AMBER, where the -CF₃ is strongly interacting with GLN189.

Zwitterionic dyad (H⁺–C⁻) isoform: In this case the FFs show quite important discrep-

ancies especially concerning the nitrile group (2). With AMBER, at variance with the form H-C, the reactive nitrile is found with high probability near the catalytic dyad with the lactame moiety (group (1)) this time bordering the S1 subsite, while in OPLS-AA, the groups (1,2) are apparently unable to approach S1 and hence C145 or H41. Also, the orientation of the central proline mimetic hydrophobic group (4)-(5) is markedly different in OPLS-AA and AMBER. While in former case, the groups (4)-(5) lingers mostly within domain I, in the latter case this group is shifted towards domain II. Finally, according to AMBER, the terminal trifluoro-group and flanking amide are solvent-exposed and not engaging in stable contacts with protein residues, while with OPLS-AA we find such group to be in strict contact with T24 and T25 in domain I.

In Figure 7 we show the 2-dimensional free energy surface (FES) with respect to the i) distance (d_x) between the C of ligand nitrile group and the S of C145 and ii) the distance (d_y) between the S of C145 and the N δ 1 of H41.

Apparently in the H-C isoform the intercalation of PF-07321332 in the binding site tend to push apart the H41-C145 pair, with the nitrile group far from C145 in both AMBER and OPLS-AA cases. According to the AMBER FF, H41 is approached by the oxo-pyrrolidine group that may help render H41 more basic and hence prone to acquire a proton from a solvating water molecule (e.g. Figure 5). Such event could trigger the formation of the thiolate-imidazolium ion pair with relocation of the ligand dyad, followed by the electrophilic attack of the nitrile Michael acceptor on the thiolate C145 and a PT from the protonated H41 to form the imine derivative. This hypothesis seems to be supported by the FES obtained with AMBER for the H⁺-C⁻ isoform (lower left panel in Figure 7) where H41 comes closer to C145 and the electrophilic reactive carbon of the nitrile group is displaced toward C145. Such mechanism does not seem to be confirmed when using OPLS-AA. In this case, the H41-C145 separation in the H-C state is less pronounced than in AMBER with the FES exhibiting a single deep minimum at $d_x \simeq 10 \text{ \AA}$ and $d_y \simeq 4 \text{ \AA}$. In the H⁺-C⁻ the mutual spatial arrangement of H41/C145 and the -CN group seems to further




Figure 7: 2D free energy surface, $f(d_x, d_y)$ computed as $f(d_x, d_y) = -RT \ln(P(d_x, d_y)/MAX[P(d_x, d_y)])$, where $P(d_x, d_y)$ denotes the joint probability of the two collective variables d_x and d_y . $d_x = C_L - S_C$ is the distance between the C of ligand nitrile group and the S of C145 and $d_y = S_C - N_H$ is the distance between the S of C145 and the N δ 1 of H41.

disfavour the Michael addition.

Dicussion

The X-ray structure of the PF-07321332-3CL^{PRO} complex is not yet available on the PDB. The X-ray structure of a strictly related alpha-keto amide 3CL^{PRO}-inhibitor (Boceprevir, PDB 7BPR)⁵⁴ refers to the covalently bound complex. There, the cyclobutyl moiety (replaced by the group 1, oxo-pyrrolidine, in PF-07321332) in the S1 pocket (S144, H163, E166), while the di-methyl-azabicyclo group (groups 4,5 in PF-07321332) is in S2 (M48, H41 Q189) with the electrophilic carbon of the intercalated dioxo warhead group bound to the

cysteinate sulphur atom. Such experimental structure of a PF-07321332 analog is quite different from that of the noncovalent complex emerged from our simulations (defined and detailed in Figure 6), especially when the protease is in the native neutral isoform H-C. As the unknown structure of the intermediate noncovalent complex can be quite different from the final covalent holo form, the picture provided by the AMBER MD simulations of the two isoforms (see Figures 6 and 7) seems to lend support to an inhibitory mechanism whereby the initial non-covalent addition of PF-07321332 to the main protease with the dyad in *neutral* form induces formation of the thiolate-imidazolium ion pair and the ligand relocation exposing the -CN group in close contact with the C145 thiolate for finalising the electrophilic attack. The formation of the zwitterionic form the non covalent neutral holo state is possibly mediated by the interaction between the oxo-pyrrolidine moiety of the ligand and H41 with the assistance of H41-bound water molecule. In the MD simulations, PF-07321332 after an initial fast assessment, seems to stabilise in the binding site of both isoforms (see Figure S3-S4 of the ESI) in an orientation not too far from that of the starting docking pose. We cannot exclude that in longer simulations major conformational or reorientational rearrangements of the ligand can occur. Such abrupt events, however, on a *single complex* are rare and generally not observed even in simulations extending in the microseconds time scale.²⁶ For example, in the *classical* MD simulations reported in Refs.²⁵⁻²⁷ (extending from a minimum of 0,1 to a maximum of 8 μ s), the ligand orientation consistently remained similar (RMSD \simeq 2.5 : 3 Å) to that of the starting pose, prepared using the X-ray with the ligand covalently bound to the cysteine, despite the former was *not covalently bound* to the protein and the cysteine was protonated.

In systems where the precise **structural features** of non-covalent binding is unknown, a reasonable approach should be based on the use of reliable docking scoring functions (such as those in Vina, see Methods section and ESI) for non covalent binding prediction, supplemented with replicates MD simulations^{25,35} for pose characterisation. The relative stability of multiple docking poses can be examined by evaluating independently their

absolute binding free using powerful nonequilibrium techniques.³⁵

Conclusions

We have studied the non-covalent interaction between PF-07321332 and the domain I+II of the SARS-CoV-2 main protease using MD simulations. The ligand was initially docked to the binding site of the two isoform of 3CL^{pro} with the catalytic dyad in the neutral and zwitterionic state using the Vina program. The resulting structures were subsequently simulated for 100 ns in the NPT ensemble in standard conditions using the amber99sb-ildn⁴² and the OPLS-AA/M FFs, producing a total simulation time of 0.4 μ s. Both FFs indicate that PF-07321332 *non-covalent* binding is likely to be stronger when the catalytic dyad is in the neutral state. When 3CL^{pro} has the H41-C145 dyad in the ionic form, while with OPLS-AA the reactive nitrile group PF-07321332 undergoes a minor rearrangement in the binding site, the AMBER FF predicts a dramatic change in the binding pattern with a close interaction between the -CN moiety, the thiolate C145 and the protonated H41. **The AMBER simulations of the neutral and zwitterionic noncovalent complexes are suggestive of a mechanism whereby the initial non-covalent addition with the dyad in neutral form induces the formation of the thiolate-imidazolium ion pair and the ligand relocation for finalising the electrophilic attack.** To further confirm the proposed mechanism, in a follow-up study, we aim at evaluating using an accurate methodology based on enhanced sampling simulations and nonequilibrium alchemy,³⁵ the absolute binding free energies of PF-07321332 non-covalent binding modes in both 3CL^{pro} isoforms.

Author Contributions

Marina Macchiagodena: Visualization, Investigation. Marco Pagliai: Visualization, Data Curation. Piero Procacci: Conceptualization, Methodology, Visualization, Investigation.

The authors: Writing- Reviewing and Editing.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors thank MIUR-Italy (“Progetto Dipartimenti di Eccellenza 2018-2022” allocated to Department of Chemistry “Ugo Schiff”) and Dr. Claudia Bello for helpful discussions.

References

- (1) Mallapaty, S. India’s massive COVID surge puzzles scientists. *Nature* **2021**, *592*, 667–668.
- (2) COVID Moonshot. 2020; <https://postera.ai/covid>, accessed June 18 2020.
- (3) Macchiagodena, M.; Pagliai, M.; Procacci, P. Identification of potential binders of the main protease 3CLpro of the COVID-19 via structure-based ligand design and molecular modeling. *Chem. Phys. Lett.* **2020**, *750*, 137489.
- (4) Sharma, J.; Kumar Bhardwaj, V.; Singh, R.; Rajendran, V.; Purohit, R.; Kumar, S. An In-silico Evaluation of Different Bioactive Molecules of Tea for Their Inhibition Potency Against Non Structural Protein-15 of SARS-CoV-2. *Food Chem.* **2021**, *346*, 128933.
- (5) Singh, R.; Bhardwaj, V. K.; Sharma, J.; Purohit, R.; Kumar, S. In-silico Evaluation of Bioactive Compounds from Tea as Potential SARS-CoV-2 Nonstructural Protein 16 Inhibitors. *J. Tradit. Complement. Med.* **2021**,

- (6) Bhardwaj, V. K.; Singh, R.; Das, P.; Purohit, R. Evaluation of Acridinedione Analogs as Potential SARS-CoV-2 Main Protease Inhibitors and Their Comparison with Repurposed Anti-viral Drugs. *Comput. Biol. Med.* **2021**, *128*, 104117.
- (7) Bhardwaj, V. K.; Singh, R.; Sharma, J.; Rajendran, V.; Purohit, R.; Kumar, S. Identification of Bioactive Molecules from Tea Plant as SARS-CoV-2 Main Protease Inhibitors. *J. Biomol. Struct. Dyn.* **2021**, *39*, 3449–3458.
- (8) Singh, R.; Bhardwaj, V. K.; Das, P.; Purohit, R. A Computational Approach for Rational Discovery of Inhibitors for Non-structural Protein 1 of SARS-CoV-2. *Comput. Biol. Med.* **2021**, *135*, 104555.
- (9) Bhardwaj, V. K.; Singh, R.; Sharma, J.; Rajendran, V.; Purohit, R.; Kumar, S. Bioactive Molecules of Tea as Potential Inhibitors for RNA-Dependent RNA Polymerase of SARS-CoV-2. *Front. Med.* **2021**, *8*, 645.
- (10) Zhai, T.; Zhang, F.; Haider, S.; Kraut, D.; Huang, Z. An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease. *Front. Mol. Biosci.* **2021**, *8*, 267.
- (11) de Vries, M.; Mohamed, A. S.; Prescott, R. A.; Valero-Jimenez, A. M.; Desvignes, L.; O'Connell, R.; Stepan, C.; Devlin, J. C.; Ivanova, E.; Herrera, A.; Schinlever, A.; Loose, P.; Ruggles, K.; Koralov, S. B.; Anderson, A. S.; Binder, J.; Dittmann, M.; Pfeiffer, J. K. A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL^{pro} Inhibitor PF-00835231 as a Potential New Treatment for COVID-19. *J. Virol.* **2021**, *95*, e01819–20.
- (12) Khan, A.; Ali, S. S.; Khan, M. T.; Saleem, S.; Ali, A.; Suleman, M.; Babar, Z.; Shafiq, A.; Khan, M.; Wei, D.-Q. Combined Drug Repurposing and Virtual Screening Strategies with Molecular Dynamics Simulation Identified Potent Inhibitors for SARS-CoV-2 Main Protease (3CL^{pro}). *J. Biomol. Struct. Dyn.* **2021**, *39*, 4659–4670.

- (13) Khan, A.; Heng, W.; Wang, Y.; Qiu, J.; Wei, X.; Peng, S.; Saleem, S.; Khan, M.; Ali, S. S.; Wei, D.-Q. In Silico and in Vitro Evaluation of Kaempferol as a Potential Inhibitor of the SARS-CoV-2 Main Protease (3CLpro). *Phytother. Res.* **2021**, *35*, 2841–2845.
- (14) Halford, B. Pfizer unveils its oral SARS-CoV-2 inhibitor. *Chem. Eng. news* **2021**, *99*.
- (15) Westberg, M.; Su, Y.; Zou, X.; Ning, L.; Hurst, B.; Tarbet, B.; Lin, M. Z. Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases. *bioRxiv* **2020**,
- (16) Dos Santos, A. M.; Cianni, L.; De Vita, D.; Rosini, F.; Leitão, A.; Laughton, C. A.; Lameira, J.; Montanari, C. A. Experimental study and computational modelling of cruzain cysteine protease inhibition by dipeptidyl nitriles. *Phys. Chem. Chem. Phys.* **2018**, *20*, 24317–24328.
- (17) *Protein Structure and Function*; Oxford University Press: Oxford (UK), 2008.
- (18) Kneller, D. W.; Phillips, G.; O'Neill, H. M.; Jedrzejczak, R.; Stols, L.; Langan, P.; Joachimiak, A.; Coates, L.; Kovalevsky, A. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. *Nat. Commun.* **2020**, *11*, 3202.
- (19) Kneller, D. W.; Phillips, G.; O'Neill, H. M.; Tan, K.; Joachimiak, A.; Coates, L.; Kovalevsky, A. Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL M^{pro}: insights into enzyme mechanism and drug design. *IUCrJ* **2020**, *7*, 1028–1035.
- (20) Kneller, D. W.; Phillips, G.; Weiss, K. L.; Pant, S.; Zhang, Q.; O'Neill, H. M.; Coates, L.; Kovalevsky, A. Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography. *J. Biol. Chem.* **2020**, *295*, 17365–17373.

- (21) *Mechanisms of protease action*; 1989; pp 123-125.
- (22) Jaskolski, M.; Dauter, Z.; Shabalina, I. G.; Gilski, M.; Brzezinski, D.; Kowiel, M.; Rupp, B.; Wlodawer, A. Crystallographic models of SARS-CoV-2 3CL^{pro}: in-depth assessment of structure quality and validation. *IUCrJ* **2021**, *8*, 238–256.
- (23) Huang, C.; Wei, P.; Fan, K.; Liu, Y.; Lai, L. 3C-like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base Mechanism. *Biochemistry* **2004**, *43*, 4568–4574.
- (24) Diaz, N.; Suarez, D. Influence of charge configuration on substrate binding to SARS-CoV-2 main protease. *Chem. Commun.* **2021**, *57*, 5314–5317.
- (25) Zanetti-Polzi, L.; Smith, M. D.; Chipot, C.; Gumbart, J. C.; Lynch, D. L.; Pavlova, A.; Smith, J. C.; Daidone, I. Tuning Proton Transfer Thermodynamics in SARS-CoV-2 Main Protease: Implications for Catalysis and Inhibitor Design. *J Phys. Chem. Lett.* **2021**, *12*, 4195–4202.
- (26) Ramos-Guzmán, C. A.; Ruiz-Pernia, J. J.; Tuñon, I. Unraveling the SARS-CoV-2 Main Protease Mechanism Using Multiscale Methods. *ACS Catalysis* **2020**, *10*, 12544–12554.
- (27) Ramos-Guzman, C.; Ruiz-Pernia, J. Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations. *ChemRxiv* **2021**,
- (28) Zhao, Q.; Li, S.; Xue, F.; Zou, Y.; Chen, C.; Bartlam, M.; Rao, Z. Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1. *J. Virol.* **2008**, *82*, 8647–8655.
- (29) Hanzlik, R. P.; Thompson, S. A. Vinylogous amino acid esters: a new class of inactivators for thiol proteases. *J. Med. Chem.* **1984**, *27*, 711–712.

- (30) Pavlova, A.; Lynch, D. L.; Daidone, I.; Zanetti-Polzi, L.; Smith, M. D.; Chipot, C.; Kneller, D. W.; Kovalevsky, A.; Coates, L.; Golosov, A. A.; Dickson, C. J.; Velez-Vega, C.; Duca, J. S.; Vermaas, J. V.; Pang, Y. T.; Acharya, A.; Parks, J. M.; Smith, J. C.; Gumbart, J. C. Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease. *Chem. Sci.* **2021**, *12*, 1513–1527.
- (31) Ponder, J. W.; Case, D. A. *Protein Simulations*; Advances in Protein Chemistry; Academic Press, 2003; Vol. 66; pp 27–85.
- (32) Robertson, M. J.; Tirado-Rives, J.; Jorgensen, W. L. Improved Peptide and Protein Torsional Energetics with the OPLS-AA Force Field. *J. Chem. Theory Comput.* **2015**, *11*, 3499–3509.
- (33) Shi, J.; Wei, Z.; Song, J. Dissection Study on the Severe Acute Respiratory Syndrome 3C-like Protease Reveals the Critical Role of the Extra Domain in Dimerization of the Enzyme: Defining the Extra Domain as a New Target for Design of Highly Specific Protease Inhibitors. *J. Biol. Chem.* **2004**, *279*, 24765–24773.
- (34) Graziano, V.; McGrath, W. J.; Yang, L.; Mangel, W. F. SARS CoV Main Proteinase: The Monomer-Dimer Equilibrium Dissociation Constant. *Biochemistry* **2006**, *45*, 14632–14641.
- (35) Macchiagodena, M.; Pagliai, M.; Karrenbrock, M.; Guarnieri, G.; Iannone, F.; Procacci, P. Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease. *J. Chem. Theory Comput.* **2020**, *16*, 7160–7172.
- (36) Trott, O.; Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **2010**, *31*, 455–461.

- (37) Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. *J. Med. Chem.* **2012**, *55*, 6582–6594.
- (38) Zev, S.; Raz, K.; Schwartz, R.; Tarabeh, R.; Gupta, P. K.; Major, D. T. Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro. *J. Chem. Inf. Model.* **2021**, *61*, 2957–2966.
- (39) Liu, X.; Zhang, B.; Jin, Z.; Yang, H.; Rao, Z. The Crystal Structure of 2019-nCoV Main Protease in Complex with an Inhibitor N3. RSCB PDB, 2020; pdbcode: 6LU7.
- (40) Li, H.; Robertson, A. D.; Jensen, J. H. Very fast empirical prediction and rationalization of protein pKa values. *Proteins* **2005**, *61*, 704–721.
- (41) Procacci, P.; Macchiagodena, M.; Pagliai, M.; Guarnieri, G.; Iannone, F. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations. *Chem. Commun.* **2020**, *56*, 8854–8856.
- (42) Lindorff-Larsen, K.; Piana, S.; Palmo, K.; Maragakis, P.; Klepeis, J. L.; Dror, R. O.; Shaw, D. E. Improved side-chain torsion potentials for the Amber ff99SB protein force field. *Proteins* **2010**, *78*, 1950–1958.
- (43) Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A. E.; Berendsen, H. J. C. GROMACS: Fast, Flexible, and Free. *J. Comput. Chem.* **2005**, *26*, 1701–1718.
- (44) Procacci, P. PrimaDORAC: A Free Web Interface for the Assignment of Partial Charges, Chemical Topology, and Bonded Parameters in Organic or Drug Molecules. *J. Chem. Inf. Model.* **2017**, *57*, 1240–1245.
- (45) Dodda, L. S.; Cabeza de Vaca, I.; Tirado-Rives, J.; Jorgensen, W. L. LigParGen web server: an automatic OPLS-AA parameter generator for organic ligands. *Nucleic Acids Res.* **2017**, *45*, W331–W336.

- (46) Pronk, S.; Páll, S.; Schulz, R.; Larsson, P.; Bjelkmar, P.; Apostolov, R.; Shirts, M. R.; Smith, J. C.; Kasson, P. M.; van der Spoel, D.; Hess, B.; Lindahl, E. GROMACS 4.5: a High-Throughput and Highly Parallel Open Source Molecular Simulation Toolkit. *Bioinformatics* **2013**, *29*, 845.
- (47) Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. *J. Chem. Phys.* **1983**, *79*, 926–935.
- (48) Pagliai, M.; Macchiagodena, M.; Procacci, P.; Cardini, G. Evidence of a Low–High Density Turning Point in Liquid Water at Ordinary Temperature under Pressure: A Molecular Dynamics Study. *J. Phys. Chem. Lett* **2019**, *10*, 6414–6418.
- (49) Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. *Protein Eng. Des. Sel.* **1995**, *8*, 127–134.
- (50) Martin-Garcia, F.; Papaleo, E.; Gomez-Puertas, P.; Boomsma, W.; Lindorff-Larsen, K. Comparing Molecular Dynamics Force Fields in the Essential Subspace. *PLOS ONE* **2015**, *10*, 1–16.
- (51) Gilson, M. K.; Given, J. A.; Bush, B. L.; McCammon, J. A. The Statistical-Thermodynamic Basis for Computation of Binding Affinities: A Critical Review. *Biophys. J.* **1997**, *72*, 1047–1069.
- (52) Procacci, P.; Chelli, R. Statistical Mechanics of Ligand-Receptor Noncovalent Association, Revisited: Binding Site and Standard State Volumes in Modern Alchemical Theories. *J. Chem. Theory Comput.* **2017**, *13*, 1924–1933.
- (53) Zhang, L.; Lin, D.; Sun, X.; Curth, U.; Drosten, C.; Sauerhering, L.; Becker, S.; Rox, K.; Hilgenfeld, R. Crystal structure of SARS-CoV-2 main protease provides a basis for

design of improved α -ketoamide inhibitors. *Science (New York, N.Y.)* **2020**, *368*, 409–412.

- (54) Fu, L.; Ye, F.; Feng, Y.; Yu, F.; Wang, Q.; Wu, Y.; Zhao, C.; Sun, H.; Huang, B.; Niu, P.; Song, H.; Shi, Y.; Li, X.; Tan, W.; Qi, J.; Gao, G. F. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. *Nature Communications* **2020**, *11*, 4417.